The Duodenal Ulcer drugs in development market research report provides comprehensive information on the therapeutics under development for Duodenal Ulcer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Duodenal Ulcer. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Duodenal Ulcer - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Duodenal Ulcer and features dormant and discontinued products.

GlobalData tracks 19 drugs in development for Duodenal Ulcer by 19 companies/universities/institutes. The top development phase for Duodenal Ulcer is phase i with nine drugs in that stage. The Duodenal Ulcer pipeline has 19 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Duodenal Ulcer pipeline products market are: Jiangsu Carephar Pharmaceutical, Dongkwang Pharma and Boryung Pharmaceutical.

The key targets in the Duodenal Ulcer pipeline products market include Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC, and Histamine H2 Receptor (Gastric Receptor I or HRH2).

The key mechanisms of action in the Duodenal Ulcer pipeline product include Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC Inhibitor with nine drugs in Phase III. The Duodenal Ulcer pipeline products include four routes of administration with the top ROA being Oral and one key molecule types in the Duodenal Ulcer pipeline products market including Small Molecule.

Duodenal Ulcer overview

Duodenal ulcers, a subset of peptic ulcer disease, result from a disruption in the mucosal surface of the duodenum, the initial segment of the small intestine. The primary culprit behind this condition is infection with Helicobacter pylori (H. pylori) bacteria. H. pylori induces inflammation in the duodenal lining, leading to ulcer formation. Certain medications, especially anti-inflammatory drugs like ibuprofen and aspirin, can also contribute to duodenal ulcers. Treatment commonly involves “triple therapy”, utilizing two antibiotics and an acid-reducing medicine. The antibiotics target bacteria, while the acid-reducing medication aids in healing the ulcer and preventing recurrence.

For a complete picture of Duodenal Ulcer’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.